Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble r… Read more
Minerva Neurosciences Inc (NERV) - Total Liabilities
Latest total liabilities as of September 2025: $62.67 Million USD
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has total liabilities worth $62.67 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Minerva Neurosciences Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Minerva Neurosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Minerva Neurosciences Inc Competitors by Total Liabilities
The table below lists competitors of Minerva Neurosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
E&E Recycling
TWO:8440
|
Taiwan | NT$116.36 Million |
|
centrotherm international AG
F:CTNK
|
Germany | €288.95 Million |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
USA | $28.43 Million |
|
Bank Victoria International
JK:BVIC
|
Indonesia | Rp29.96 Trillion |
|
S-Fuelcell co. Ltd
KQ:288620
|
Korea | ₩47.10 Billion |
|
CrownHaitai Holdings Co Ltd Preference Shares
KO:005745
|
Korea | ₩610.92 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Minerva Neurosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Minerva Neurosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Minerva Neurosciences Inc (2012–2024)
The table below shows the annual total liabilities of Minerva Neurosciences Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $62.84 Million | -26.38% |
| 2023-12-31 | $85.36 Million | +13.64% |
| 2022-12-31 | $75.11 Million | +8.63% |
| 2021-12-31 | $69.15 Million | +1293.06% |
| 2020-12-31 | $4.96 Million | -90.02% |
| 2019-12-31 | $49.72 Million | +1.74% |
| 2018-12-31 | $48.87 Million | -6.20% |
| 2017-12-31 | $52.10 Million | +93.25% |
| 2016-12-31 | $26.96 Million | -1.09% |
| 2015-12-31 | $27.26 Million | +60.80% |
| 2014-12-31 | $16.95 Million | +88.44% |
| 2013-12-31 | $9.00 Million | +4627.09% |
| 2012-12-31 | $190.29K | -- |